Physician profile
Christopher A Coleman
NPI 1447219282
$2,632.37
in general payments reported to CMS, 2019-2025
13 companies · $1,260 in 2025
The $1,260 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $444 · 2020: $51.54 · 2021: $130 · 2022: $196 · 2023: $162 · 2024: $389 · 2025: $1,260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,000 · Food and Beverage: $750 · Entertainment: $60.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,000.00 |
| Food and Beverage | $749.80 |
| Entertainment | $60.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,372.71 | 2019-2025 | Precision 1, Air Optix Color, Dailies Total1 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $272.35 | 2019 | |
| Bausch & Lomb Americas INC. | $235.16 | 2022-2025 | Biotrue One Day, Btod, Infuse |
| Lkc Technologies, INC. | $157.04 | 2024 | |
| Johnson & Johnson Vision Care, INC. | $148.76 | 2019-2024 | Acuvue |
| Coopervision INC. | $129.99 | 2019-2024 | Myday Contact Lens, Clariti Contact Lens, Biofinity Contact Lens |
| Tarsus Pharmaceuticals, INC. | $121.84 | 2025 | Xdemvy |
| Optos, INC. | $60.53 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Maculogix, INC. | $45.51 | 2019 | |
| Oyster Point Pharma, INC. | $37.21 | 2022-2024 | Tyrvaya |
| Kala Pharmaceuticals, INC. | $24.87 | 2021 | |
| Abbvie INC. | $14.92 | 2022 | |
| Allergan, INC. | $11.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Coleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.